Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387233944> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4387233944 endingPage "73" @default.
- W4387233944 startingPage "62" @default.
- W4387233944 abstract "OBJECTIVES: To review the prescription of Intravenous immunoglobulin (IVIg) in neurological disease regarding its efficacy, prescription pattern, indication and treatment outcome. MATERIALS AND METHODS: We studied IVIg usage and treatment outcomes by reviewing the prescription database and medical records from 2013 to 2019 at Thammasat University Hospital (TUH), which is the university hospital in the lower central region of Thailand, and records at Bangkok International Hospital (BIH), part of the largest private hospital network in Thailand. RESULTS: IVIg was used in 28 patients in TUH and 86 patients in BIH. The diagnoses were Guillain-Barré syndrome (GBS) (50%), myasthenia gravis (MG) crisis (23%) and chronic inflammatory demyelinating polyneuropathy (CIDP) (6%). 39.5% of patients were prescribed IVIg apart from those prescribed in line with the Thailand national list of essential medicine (NLEM) indication. The major cause of NLEM deviation is usage beyond reimbursement guidelines, but the dose of IVIg administered is within standard guidelines. IVIg usage and treatment outcomes were similar in both hospitals in the case of GBS and MG. Both groups show beneficial outcomes from IVIg. BIH used IVIg often as first line treatment for CIDP, but TUH used IVIg as subsequent therapy after failure of corticosteroid administration. TUH preferred plasmapheresis combined with a high dose steroid for neuromyelitis optica spectrum disorder (NMOSD) and autoimmune encephalitis reflecting the cost of therapy and reimbursement guidelines. CONCLUSION: IVIg is still the mainstay treatment of GBS and MG crisis in Thailand. The outcome of GBS and MG crisis is similar in both hospitals. Private hospitals seem to have more off label use and often used IVIg as a first line therapy in CIDP, NMOSD and autoimmune encephalitis. Reimbursement guidelines and NLEM have a major impact on prescription patterns." @default.
- W4387233944 created "2023-10-02" @default.
- W4387233944 creator A5059317319 @default.
- W4387233944 creator A5092980018 @default.
- W4387233944 date "2023-09-30" @default.
- W4387233944 modified "2023-10-16" @default.
- W4387233944 title "A Retrospective Review of Real-life Practice of Intravenous Immunoglobulin Usage in Autoimmune Neurological Disease" @default.
- W4387233944 doi "https://doi.org/10.31524/bkkmedj.2023.21.001" @default.
- W4387233944 hasPublicationYear "2023" @default.
- W4387233944 type Work @default.
- W4387233944 citedByCount "0" @default.
- W4387233944 crossrefType "journal-article" @default.
- W4387233944 hasAuthorship W4387233944A5059317319 @default.
- W4387233944 hasAuthorship W4387233944A5092980018 @default.
- W4387233944 hasBestOaLocation W43872339441 @default.
- W4387233944 hasConcept C126322002 @default.
- W4387233944 hasConcept C159654299 @default.
- W4387233944 hasConcept C160735492 @default.
- W4387233944 hasConcept C162324750 @default.
- W4387233944 hasConcept C177713679 @default.
- W4387233944 hasConcept C187212893 @default.
- W4387233944 hasConcept C203014093 @default.
- W4387233944 hasConcept C2426938 @default.
- W4387233944 hasConcept C2778105408 @default.
- W4387233944 hasConcept C2778842783 @default.
- W4387233944 hasConcept C2779134260 @default.
- W4387233944 hasConcept C2779703844 @default.
- W4387233944 hasConcept C2780640218 @default.
- W4387233944 hasConcept C2781137167 @default.
- W4387233944 hasConcept C50522688 @default.
- W4387233944 hasConcept C71924100 @default.
- W4387233944 hasConcept C98274493 @default.
- W4387233944 hasConceptScore W4387233944C126322002 @default.
- W4387233944 hasConceptScore W4387233944C159654299 @default.
- W4387233944 hasConceptScore W4387233944C160735492 @default.
- W4387233944 hasConceptScore W4387233944C162324750 @default.
- W4387233944 hasConceptScore W4387233944C177713679 @default.
- W4387233944 hasConceptScore W4387233944C187212893 @default.
- W4387233944 hasConceptScore W4387233944C203014093 @default.
- W4387233944 hasConceptScore W4387233944C2426938 @default.
- W4387233944 hasConceptScore W4387233944C2778105408 @default.
- W4387233944 hasConceptScore W4387233944C2778842783 @default.
- W4387233944 hasConceptScore W4387233944C2779134260 @default.
- W4387233944 hasConceptScore W4387233944C2779703844 @default.
- W4387233944 hasConceptScore W4387233944C2780640218 @default.
- W4387233944 hasConceptScore W4387233944C2781137167 @default.
- W4387233944 hasConceptScore W4387233944C50522688 @default.
- W4387233944 hasConceptScore W4387233944C71924100 @default.
- W4387233944 hasConceptScore W4387233944C98274493 @default.
- W4387233944 hasIssue "02" @default.
- W4387233944 hasLocation W43872339441 @default.
- W4387233944 hasOpenAccess W4387233944 @default.
- W4387233944 hasPrimaryLocation W43872339441 @default.
- W4387233944 hasRelatedWork W1969696638 @default.
- W4387233944 hasRelatedWork W2182069318 @default.
- W4387233944 hasRelatedWork W2289159721 @default.
- W4387233944 hasRelatedWork W2396962048 @default.
- W4387233944 hasRelatedWork W2492545249 @default.
- W4387233944 hasRelatedWork W2617809749 @default.
- W4387233944 hasRelatedWork W2738038524 @default.
- W4387233944 hasRelatedWork W3153243949 @default.
- W4387233944 hasRelatedWork W31656499 @default.
- W4387233944 hasRelatedWork W75008956 @default.
- W4387233944 hasVolume "19" @default.
- W4387233944 isParatext "false" @default.
- W4387233944 isRetracted "false" @default.
- W4387233944 workType "article" @default.